

SLC22A5 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP8854c

Specification

SLC22A5 Antibody (Center) Blocking Peptide -Product Information

Primary Accession 076082

SLC22A5 Antibody (Center) Blocking Peptide -Additional Information

Gene ID 6584

Other Names

Solute carrier family 22 member 5, High-affinity sodium-dependent carnitine cotransporter, Organic cation/carnitine transporter 2, SLC22A5, OCTN2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP8854c was selected from the Center region of human SLC22A5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLC22A5 Antibody (Center) Blocking Peptide - Protein Information

Name SLC22A5

SLC22A5 Antibody (Center) Blocking Peptide - Background

SLC22A5 is a plasma integral membrane protein which functions both as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. The encoded protein is involved in the active cellular uptake of carnitine.

SLC22A5 Antibody (Center) Blocking Peptide - References

Bacher, P., et.al., Biochim. Biophys. Acta 1788 (12), 2594-2602 (2009)



Synonyms OCTN2

Function

Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.

Cellular Location

Membrane; Multi- pass membrane protein

Tissue Location

Strongly expressed in kidney, skeletal muscle, heart and placenta. Highly expressed in intestinal cell types affected by Crohn disease, including epithelial cells. Expressed in CD68 macrophage and CD43 T-cells but not in CD20 B-cells

SLC22A5 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides